tbuckley/cabot-search huggingface dataset:
Demonstration that platelet-expressed human B-domainless Factor VIII can ameliorate the bleeding diathesis in a murine model of hemophilia A
Authors: H. E. Yarovoi, M. S. King, D. E. Eslin, S. L. Heberichter, Q. Shi, M. A. na Kowalska, D. A. Wilcox, B. S. Sachais, R. R. Montgomery, M. Poncz
Journal: Blood (2003)
Sputum Mast Cells and Eosinophils Identify Asthmatics with Lower Lung Function and Proneness to Exacerbations
Authors: Merritt L. Fajt, Michael Peters, Eugene R. Bleecker, Juan Carlos Cardet, Mario Castro, Suzy Comhair, Andrea Coverstone, Loren C. Denlinger, Serpil C. Erzurum, Annette T. Hastie, Elliot Israel, Nizar N. Jarjour, Mats W. Johansson, Bruce D. Levy, David M. Mauger, Stephen P. Peters, Brenda R. Phillips, Wanda Phipatanakul, Kristie R. Ross, Sima K. Ramratnam, John V. Fahy, Sally Wenzel
Journal: Journal of Allergy and Clinical Immunology (2018)
Randomized, placebo controlled, phase III trial of low-dose tamoxifen in women with intraepithelial neoplasia.
Authors: Matteo Puntoni, Bernardo Bonanni, Giuseppe D'Aiuto, Antonio Ponti, Maria Grazia Paquola, Laura Cortesi, Cosimo D'Amico, Marcella Gulisano, Giorgio Cruciani, Fabio Falcini, Giovanni Giardina, Katia Cagossi, Lea Regolo, Mariuccia Renne, Giuseppe Canavese, Daniela Branchi, Domenico Marra, Aliana Guerrieri-Gonzaga, Harriet Ann Johansson, Andrea De Censi
Journal: Journal of Clinical Oncology (2013)

TPS1610 Background: Breast IntraEpithelial Neoplasia (IEN) is associated with a 8-10 fold increased risk of invasive disease, thus representing an important target for chemoprevention. The NSABP-P1 trial showed that tamoxifen (TAM) at 20 mg/day is associated with a 86% reduction of invasive breast cancer (BC) in women with previous atypical ductal hyperplasia (ADH) (RR=0.14, 95% IC, 0.03-0.47) and with a 56% risk reduction in women with previous LCIS (RR=0.44, 0.16-1.06). However, TAM broad use in chemoprevention has been significantly hampered by the increased risk of endometrial cancer and of venous thromboembolism (VTE). We recently showed that a dose of 5 mg/day does not increase endometrial proliferation, is associated with a decrease of the estrogenic activity of TAM on IGF-I, SHBG and antithrombin-III, and attains at the breast tissue level a concentration 10 times higher than that needed to inhibit cell growth in vitro. The CYP2D6 enzyme mediates oxidation of N-desmethyl tamoxifen to endoxifen, the most active metabolite of TAM. The SNP CYP2D6*4 (1846G&gt;A) allele accounts for 75% of poor metabolizer phenotype which have been associated with a higher risk of a breast event compared to wildtype (Pharmacogenomics J. 2011;11:100-7). Methods: A randomized double-blind placebo-controlled phase III trial to assess the efficacy and safety of 5 mg/day TAM vs. placebo for 3 years in women with previous IEN (LIN 2-3 and ER+ or unknown DIN 1b-3). In Europe TAM is not registered in women with prior DCIS. 1400 women are needed to detect 50% reduction in the incidence of BC in the TAM arm (80% power, 1-sided 5% α error). Secondary endpoints are: incidence of other non-invasive breast disorders, endometrial cancer, clinical bone fractures, cardiovascular events, VTE events, and clinically manifest cataract. Pharmacogenetic endpoints includes the association between CYP2D6 genotype and modulation of biomarkers of TAM efficacy and safety (circulating IGF-I, hormones, mammographic density, endometrial thickness and hot flashes) and clinical events. As of February 5, 2013, 18 enrolment centers have been activated and n=338 women have been randomized. No suspected unexpected serious adverse reactions were registered. Clinical trial information: NCT01357772.
Treatment Sequencing Patterns Observed in Patients Treated Initially with Lenalidomide/Dexamethasone Combination As Frontline Multiple Myeloma Therapy
Authors: Clara Chen, Ravi Potluri, Hemanth Kanakamedala, Eros Papademetriou, Christopher A. Yasenchak, Sandip Ranjan, Hitesh Bhandari, Jasdeep Mann, Catherine Davis
Journal: Blood (2017)
Real-Life Patterns of Short-Acting Beta-Agonist Use in Persistent Asthmatics Vary by Age, Time of Day, and Season
Authors: William Anderson, John Brinton, Leanne Kaye, Heather Hoch, Meredith Barrett, David Van Sickle, Stanley J. Szefler, David A. Stempel
Journal: Journal of Allergy and Clinical Immunology (2018)
The usefulness of tryptase formula for the diagnosis of shrimp-induced anaphylaxis
Authors: Thunyatorn Phisitbuntoon, Patcharaporn Wongkaewpothong, Punchama Pacharn, Nualanong Visitsunthorn, Pakit Vichyanond, Orathai Jirapongsananuruk
Journal: Journal of Allergy and Clinical Immunology (2018)
Neoadjuvant Systemic Therapy for Breast Cancer
Authors: Joseph A. Sparano
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
CD8+ Anti-BCMA mRNA CAR T-Cells Effectively Kill Human Multiple Myeloma Cells In Vitro and In Vivo
Authors: Liang Lin, Lijie Xing, Chirag M Acharya, Kenneth Wen, Jiye Liu, Phillip Hsieh, Metin Kurtoglu, Jeffrey Holderness, Murat Kalayoglu, Nikhil Munshi, Paul G Richardson, Kenneth C Anderson, Yu-Tzu Tai
Journal: Blood (2017)
The Transcription Factor STAT6 Mediates Direct Repression of Inflammatory Enhancers and Limits Activation of Alternatively Polarized Macrophages
Authors: Zsolt Czimmerer, Bence Daniel, Attila Horvath, Dominik Rückerl, Gergely Nagy, Mate Kiss, Matthew Peloquin, Marietta M. Budai, Ixchelt Cuaranta-Monroy, Zoltan Simandi, Laszlo Steiner, Bela Nagy, Szilard Poliska, Csaba Banko, Zsolt Bacso, Ira G. Schulman, Sascha Sauer, Jean-Francois Deleuze, Judith E. Allen, Szilvia Benko, Laszlo Nagy
Journal: Immunity (2018)

The molecular basis of signal-dependent transcriptional activation has been extensively studied in macrophage polarization, but our understanding remains limited regarding the molecular determinants of repression. Here we show that IL-4-activated STAT6 transcription factor is required for the direct transcriptional repression of a large number of genes during in vitro and in vivo alternative macrophage polarization. Repression results in decreased lineage-determining transcription factor, p300, and RNA polymerase II binding followed by reduced enhancer RNA expression, H3K27 acetylation, and chromatin accessibility. The repressor function of STAT6 is HDAC3 dependent on a subset of IL-4-repressed genes. In addition, STAT6-repressed enhancers show extensive overlap with the NF-κB p65 cistrome and exhibit decreased responsiveness to lipopolysaccharide after IL-4 stimulus on a subset of genes. As a consequence, macrophages exhibit diminished inflammasome activation, decreased IL-1β production, and pyroptosis. Thus, the IL-4-STAT6 signaling pathway establishes an alternative polarization-specific epigenenomic signature resulting in dampened macrophage responsiveness to inflammatory stimuli.
Abstract 19976: Flow Mediated Dilatation is Responsible For Abnormal Blood Pressure Response on Exercise in Patients With Hypertrophic Cardiomyopathy and Syncope
Authors: Riccardo Morgagni, Ambrogio Capria, Marco Perrone, Alfredo Intorcia, Francesco Romeo
Journal: Circulation (2016)

Introduction: Hypertrophic Cardiomyopathy (HCM) is an inherited myocardial disease characterized by unexplained increased left ventricular wall thickness associated with non-dilated ventricular cha...
Cambios notables en la epidemiología de los lisotipos de Salmonella enterica serotipo Enteritidis en Europa occidental de 1998 a 2003 – los resultados de la base de datos internacional Enter-net sobre las salmonelas
Authors: I. S.T. Fisher
Journal: Eurosurveillance (2004)

En Europa occidental, Salmonella enterica serotipo Enteritidis es el serotipo de salmonela mas frecuentemente identificado por los laboratorios nacionales de referencia de Enter-net. Por tanto, resulta primordial realizar un lisotipado para la deteccion y confirmacion de las epidemias y las tendencias de las infecciones. Segun los datos de la base de datos de Enter-net sobre salmonelas, se ha observado un cambio muy importante en los lisotipos identificados en Europa entre 1998 y 2003. En 1998, el lisotipo PT4 era el mas frecuentemente identificado en los humanos (61,8%, 21.630 casos). En 2003, la proporcion de PT4 paso a ser de 32,1% (8.794 casos), en tanto otras cepas aumentaban en numero absoluto y en proporcion. Este articulo identifica las cepas emergentes que estan adquiriendo mas importancia en terminos de salud publica.
Winter pressure: government responses across UK
Authors: Zosia Kmietowicz
Journal: BMJ (2018)

Health services across the UK have been facing unprecedented pressure in the past week. Chaand Nagpaul, chair of the BMA’s council, described the NHS as “congested and overstretched,” adding, “We urgently need more long term planning to ensure the NHS can meet rising demand on services and has the capacity to deal with the inevitable spike in demand each winter.”

His call was echoed by Jane Dacre, president of the Royal College of Physicians. “Our physician members . . . have told us that the NHS is in a state of perennial winter,” she said. “We need long term solutions, not short term fixes.”

With hospital bed occupancy at …
Plasminogen activator inhibitor 1 (PAI-1) level and lung function over 30 years: the CARDIA study
Authors: Michael G. Sherenian, Michael J. Cuttica, Sadiya S. Khan, Laura A. Colangelo, Joan Cook-Mills, Seong Ho Cho, Myriam Fornage, Myron Gross, David Jacobs, Pamela Schreiner, Douglas Vaughn, Donald Lloyd-Jones, Ravi Kalhan, Rajesh Kumar
Journal: Journal of Allergy and Clinical Immunology (2018)
Safety of amoxicillin provocation test using the PSU 2-step challenge in children with a history of non-immediate reactions
Authors: Vanlaya Koosakulchai, Duangdee Wantanaset, Wipa Jessadapakorn, Pasuree Sangsupawanich, Araya Yuenyongviwat, Thatchai Wirodwanich
Journal: Journal of Allergy and Clinical Immunology (2018)
Chlamydia trachomatis and the risk of spontaneous preterm birth, babies who are born small for gestational age, and stillbirth: a population-based cohort study
Authors: Joanne Reekie, Christine Roberts, David Preen, Jane S Hocking, Basil Donovan, James Ward, Donna B Mak, Bette Liu, Bette Liu, David Preen, Jane Hocking, Basil Donovan, Christine Roberts, James Ward, Donna Mak, Rebecca Guy, John Kaldor, Sallie-Anne Pearson, Louise Stewart, Handan Wand, Joanne Reekie
Journal: The Lancet Infectious Diseases (2018)
A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk
Authors: Steven C Moore, Mary C Playdon, Joshua N Sampson, Robert N Hoover, Britton Trabert, Charles E Matthews, Regina G Ziegler
Journal: JNCI Journal of the National Cancer Institute (2017)

Elevated body mass index (BMI) is associated with increased risk of postmenopausal breast cancer. The underlying mechanisms, however, remain elusive. In a nested case–control study of 621 postmenopausal breast cancer case participants and 621 matched control participants, we measured 617 metabolites in prediagnostic serum. We calculated partial Pearson correlations between metabolites and BMI, and then evaluated BMI-associated metabolites (Bonferroni-corrected α level for 617 statistical tests = P < 8.10 × 10-5) in relation to invasive breast cancer. Odds ratios (ORs) of breast cancer comparing the 90th vs 10th percentile (modeled on a continuous basis) were estimated using conditional logistic regression while controlling for breast cancer risk factors, including BMI. Metabolites with the lowest P values (false discovery rate < 0.2) were mutually adjusted for one another to determine those independently associated with breast cancer risk. Of 67 BMI-associated metabolites, two were independently associated with invasive breast cancer risk: 16a-hydroxy-DHEA-3-sulfate (OR = 1.65, 95% confidence interval [CI] = 1.22 to 2.22) and 3-methylglutarylcarnitine (OR = 1.67, 95% CI = 1.21 to 2.30). Four metabolites were independently associated with estrogen receptor–positive (ER+) breast cancer risk: 16a-hydroxy-DHEA-3-sulfate (OR = 1.84, 95% CI = 1.27 to 2.67), 3-methylglutarylcarnitine (OR = 1.91, 95% CI = 1.23 to 2.96), allo-isoleucine (OR = 1.76, 95% CI = 1.23 to 2.51), and 2-methylbutyrylcarnitine (OR = 1.89, 95% CI = 1.22 to 2.91). In a model without metabolites, each 5 kg/m2 increase in BMI was associated with a 14% higher risk of breast cancer (OR = 1.14, 95% CI = 1.01 to 1.28), but adding 16a-hydroxy-DHEA-3-sulfate and 3-methylglutarylcarnitine weakened this association (OR = 1.06, 95% CI = 0.93 to 1.20), with the logOR attenuating by 57.6% (95% CI = 21.8% to 100.0+%). These four metabolites may signal metabolic pathways that contribute to breast carcinogenesis and that underlie the association of BMI with increased postmenopausal breast cancer risk. These findings warrant further replication efforts.
Preliminary indications regarding the safety and efficacy potential of allergen bearing bioparticles as an evolved form of immunotherapy
Authors: Guy Tropper, Veronique M. Gomord, Virginie Stordeur, Brian J. Ward, Sébastien Viel, Elizabeth D. Fixman, Anne-Catherine Fitchette, Lorna Garnier, Louis-Philippe Vézina, Loic J-Y Faye
Journal: Journal of Allergy and Clinical Immunology (2018)
Onboarding Experience of Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin 10%
Authors: Sudhir Gupta, Iftikhar Hussain, Kenneth Paris, Mark Stein, Barbara McCoy, Ping Wang, Christopher J. Rabbat, Leman Yel
Journal: Journal of Allergy and Clinical Immunology (2018)
Selecting between HLA-Matched Siblings and HLA- Haploidentical Related Donors for Acute Leukemia in the Era of Post-Transplant Cyclophosphamide: The Center for International Blood and Marrow Transplant Registry and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplant
Authors: Tara M. Robinson, Ephraim J. Fuchs, Mei-Jie Zhang, Myriam Labopin, Andrew St. Martin, Daniel A Keesler, Didier Blaise, Asad Bashey, Jean-Henri Bourhis, Fabio Ciceri, Stefan O. Ciurea, Steven M. Devine, Mohamad Mohty, Shannon R. McCurdy, Noel Milpied, Ian K. McNiece, Vanderson Rocha, Rizwan Romee, Gerard Socie, Ibrahim Yakoub-Agha, Robert J. Soiffer, Mary Eapen, Arnon Nagler
Journal: Blood (2017)
Restoring Body Image After Cancer (ReBIC): Results of a Randomized Controlled Trial
Authors: Mary Jane Esplen, Jiahui Wong, Ellen Warner, Brenda Toner
Journal: Journal of Clinical Oncology (2018)

Purpose This study aimed to test a group psychosocial intervention focused on improving disturbances of body image (BI), sexual functioning, and quality of life in breast cancer (BC) survivors. Methods A prospective, randomized controlled trial was conducted to assess the efficacy of an 8-week group intervention in women after BC treatment. The manual-based intervention combined two powerful ingredients: expressive guided-imagery exercises integrated within a model of group-therapy principles. The intervention facilitates exploration of identity, the development of new self-schemas, and personal growth. In addition, the intervention included an educational component on the social and cultural factors affecting women's self-esteem and BI. The control condition included standard care plus educational reading materials. One hundred ninety-four BC survivors who had expressed concerns about negative BI and/or difficulties with sexual functioning participated in the study; 131 were randomly assigned to the intervention, and 63 were assigned to the control condition. Participants were followed for 1 year. Results Women in the intervention group reported significantly less concern/distress about body appearance ( P < .01), decreased body stigma ( P < .01), and lower level of BC-related concerns ( P < .01), compared with women in the control group. BC-related quality of life was also better in the intervention group compared with the control group at the 1-year follow-up ( P < .01). There was no statistically significant group difference in sexual functioning. Conclusion Restoring Body Image After Cancer (ReBIC), a group intervention using guided imagery within a group-therapy approach, is an effective method for addressing BI-related concerns and quality of life post-BC. The manual-based intervention can be easily adapted to both cancer centers and primary care settings.
Pegylated Carboxyhemoglobin Bovine (SANGUINATE®) Restores RBCs Roundness and Reduces Pain during a Sickle Cell Vaso-Occlusive Crisis
Authors: Peter Buontempo, Ronald G. Jubin, Cathy Buontempo, Rosa Real, Friedericke Kazo, Siobhan O'Brien, Faiza Adeel, Abraham Abuchowski
Journal: Blood (2017)
The dual ABL/SRC inhibitors dasatinib, SKI-606, and INNO-406 are potent inhibitors of T cell acute lymphoblastic leukemia cell lines expressing the NUP214-ABL1 fusion kinase
Authors: Alfonso Quintas-Cardama, Taghi Manshouri, Weigang Tong, Hagop Kantarjian, Jorge Cortes, Guillermo Garcia-Manero
Journal: Cancer Research (2007)

1825  The fusion of ABL1 with BCR results in the hybrid BCR-ABL1 oncogene that encodes the constitutively active Bcr-Abl tyrosine kinase encountered in the majority of patients (pts) with chronic myeloid leukemia and in approximately 30% of pts with B-cell acute lymphoblastic leukemia (B-ALL). Episomal amplification of ABL1 has been described in ~6% of pts with T-ALL, in whom this oncogene is found fused with the nuclear pore complex protein NUP214 (NUP214-ABL1). This transcript has been identified in 3 human T-ALL cell lines (PEER, BE-13, and SIL-ALL) among 22 evaluated, providing a framework for the in vitro study of NUP214-ABL1-positive leukemia. Preliminary data from our group suggest that dasatinib has superior activity against NUP214-ABL1-expressing cell lines compared with imatinib and nilotinib. In the present study, we evaluated the activity of the dual Abl/Src tyrosine kinase inhibitors (TKIs) dasatinib, SKI-606, and INNO-406 against the human NUP214-ABL1-expressing PEER cell line. Exposure to dasatinib, SKI-606, or INNO-406 for 72 hours (MTS assay) inhibited proliferation of PEER cells with IC50 values of 39 nM, 64 nM, and 86 nM, respectively. In contrast, Jurkat cells, a NUP214-ABL1-negative T-ALL cell line, were remarkably resistant to these TKIs with an IC50 values greater than 5 μM, indicating that the cytotoxicity mediated by these compounds is not related to a general toxic effect on T-ALL cell lines. Treatment of PEER cells with equipotent concentrations of dasatinib, SKI-606, and INNO-406 induced mitochondrial potential loss (chloromethyl-X-rosamine; CMX-Ros) and activation of caspase-3 (Phi-Phi-Lux-G1D2) as evidenced by flow cytometry, which resulted in marked dose- and time-dependent induction of apoptosis. Treatment for 72 hours with dasatinib, SKI-606, and INNO-406 at their respective IC50 concentrations resulted in apoptosis of 46%, 51%, and 53% of PEER cells by annexin V-propidium iodide staining. In experiments focused on cell cycle analysis, exposure to equipotent doses of dasatinib, SKI-606, and INNO-406 for 72 hours, resulted in accumulation of 47.61%, 63.53%, and 57.81% of PEER cells in sub-G1 phase, respectively. Treatment of PEER cells with the 3 TKIs at concentrations ranging from 1 nM to 100 nM for 3 hours resulted in remarkable decrease in CrKL phosphorylation as determined by Western blot. CrKL phosphorylation was inhibited almost completely with all 3 TKIs at concentrations above 10 nM. By contrast, exposure to nilotinib resulted in inhibition of CrKL phophorylation only at concentrations greater than 100 nM.  We conclude that dasatinib, SKI-606, and INNO-406 have significant activity against NUP214-ABL1-positive cells and represent promising therapeutic approaches in the context of NUP214-ABL1-positive leukemia that warrant further investigation in clinicaltrials.
Constructive episodic simulation, flexible recombination, and memory errors
Authors: Daniel L. Schacter, Alexis C. Carpenter, Aleea Devitt, Reece P. Roberts, Donna Rose Addis
Journal: Behavioral and Brain Sciences (2018)

Abstract According to Mahr &amp; Csibra (M&amp;C), the view that the constructive nature of episodic memory is related to its role in simulating future events has difficulty explaining why memory is often accurate. We hold this view, but disagree with their conclusion. Here we consider ideas and evidence regarding flexible recombination processes in episodic retrieval that accommodate both accuracy and distortion.
Percutaneous-endoscopic rendezvous procedure for the management of bile duct injuries after cholecystectomy: short- and long-term outcomes
Authors: Anne Schreuder, Klaske Booij, Philip de Reuver, Otto van Delden, Krijn van Lienden, Marc Besselink, Olivier Busch, Dirk Gouma, Erik Rauws, Thomas van Gulik
Journal: Endoscopy (2018)

Abstract Background Bile duct injury (BDI) remains a daunting complication of laparoscopic cholecystectomy. In patients with complex BDI, a percutaneous-endoscopic rendezvous procedure may be required to establish bile duct continuity. The aim of this study was to assess short- and long-term outcomes of the rendezvous procedure. Methods All consecutive patients with BDI referred to our tertiary referral center between 1995 and 2016 were analyzed. A rendezvous procedure was performed when endoscopic or radiologic intervention failed, and when deemed feasible by a dedicated multidisciplinary team including hepatopancreaticobiliary surgeons, gastrointestinal endoscopists, and interventional radiologists. Classification of BDI, technical success of the rendezvous procedure, procedure-related adverse events, and outcomes were assessed. Results Among a total of 812 patients, rendezvous was performed in 47 (6 %), 31 (66 %) of whom were diagnosed with complete transection of the bile duct (Amsterdam type D/Strasberg type E injury). The primary success rate of rendezvous was 94 % (44 /47 patients). Overall morbidity was 18 % (10 /55 procedures). No life-threatening adverse events or 90-day mortality occurred. After a median follow-up of 40 months (interquartile range 23 – 54 months), rendezvous was the final successful treatment in 26 /47 patients (55 %). In 14 /47 patients (30 %), rendezvous acted as a bridge to surgery, with hepaticojejunostomy being chosen either primarily or secondarily to treat refractory or relapsing stenosis. Conclusions In experienced hands, rendezvous was a safe procedure, with a long-term success rate of 55 %. When endoscopic or transhepatic interventions fail to restore bile duct continuity in patients with BDI, rendezvous should be considered, either as definitive treatment or as a bridge to elective surgery.